Name | Description | Official Website | Industry | Launch Date | Product Parent Company | ||
|---|---|---|---|---|---|---|---|
Prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension. | |||||||
GD2-binding monoclonal antibody indicated. | |||||||
Prostacyclin mimetic indicated for treatment of pulmonary arterial hypertension. | |||||||
Phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH). | |||||||
TYVASO is approved for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve the ability to exercise. |